Cargando...
Complete response in a patient with lung cancer suffering from three pembrolizumab‐induced immune‐related adverse events including retinal vasculitis
A 71‐year‐old man was diagnosed with squamous cell lung carcinoma with high expression of programmed cell death ligand 1 (PDL1) (cT4N1M1b stage IVA). He was treated with pembrolizumab, but 14 days later, he suffered from pembrolizumab‐related retinal vasculitis as an immune‐related adverse event (ir...
Guardado en:
| Publicado en: | Respirol Case Rep |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley & Sons, Ltd
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7938210/ https://ncbi.nlm.nih.gov/pubmed/33732464 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.730 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|